Literature DB >> 12669310

Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential.

Tyler Lahusen1, Adriana De Siervi, Conrad Kunick, Adrian M Senderowicz.   

Abstract

The majority of human neoplasms have aberrations in the retinoblastoma pathway due to hyperactivation of cyclin-dependent kinases (CDK). Based on this observation, novel small molecules, such as flavopiridol and UCN-01, are being developed and are currently being tested in the clinic. Efforts to develop CDK modulators led us to the discovery of a novel class of CDK inhibitors, the paullones [Cancer Res 1999;59:2566]. Initial studies demonstrated that paullones inhibit CDKs in vitro, thereby blocking cell-cycle progression. However, the exact mechanism for the antiproliferative effects of paullones was never explored. In this report, we demonstrate for the first time that the most potent paullone, alsterpaullone (Alp), induced apoptosis and promoted loss in clonogenicity in the Jurkat cell line. Alp caused early activation of both caspase-8 and -9, leading to cleavage of caspase-3 and poly(ADP-ribose) polymerase (PARP). Moreover, apoptosis by Alp was not associated with loss in anti-apoptotic proteins such as XIAP or BCL-XL. Pre-incubation with cell-permeable inhibitors z-Asp(OMe)-Glu(OMe)-Val-Asp(Ome)-fluoromethylketone and benzyloxycarbonyl-Val-Ala-Asp (OMe)-fluoromethylketone (ZVAD) blocked Alp-induced apoptosis. Moreover, the general caspase inhibitor ZVAD blocked the cleavage and activation of most caspases tested except caspase-9. Studies of mitochondrial membrane potential also demonstrated that Alp is able to disrupt mitochondrial potential in the presence of ZVAD, suggesting that the activation of caspase-9 by Alp follows mitochondrial perturbation. Pre-incubation of Jurkat cells with ZVAD did not prevent the depletion of cyclin D3, loss of CDK, or cell-cycle arrest by Alp. In summary, these experiments suggest that Alp activates caspase-9 via mitochondrial perturbation. Active caspase-9 cleaves and activates caspase-8 and caspase-3, leading to apoptosis. In the presence of the general caspase inhibitor ZVAD, the cell-cycle effects of Alp are unaltered while apoptosis is blocked, suggesting that the CDK effects of Alp are not sufficient for Alp-induced apoptosis. Additional studies with paullones are warranted to further characterize their preclinical effects and to explore their potential use in the clinical setting. Published 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12669310     DOI: 10.1002/mc.10114

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  19 in total

1.  Candidate agents for papillary thyroid cancer identified by gene expression analysis.

Authors:  Wei Zhu; Chen Li; Zhilong Ai
Journal:  Pathol Oncol Res       Date:  2013-03-22       Impact factor: 3.201

2.  FGF inhibits the activity of the cyclin B1/CDK1 kinase to induce a transient G₂arrest in RCS chondrocytes.

Authors:  Tri Tran; Victoria Kolupaeva; Claudio Basilico
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

3.  BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer.

Authors:  Paola De Luca; Elba S Vazquez; Cristian P Moiola; Florencia Zalazar; Javier Cotignola; Geraldine Gueron; Kevin Gardner; Adriana De Siervi
Journal:  Mol Cancer Res       Date:  2011-06-23       Impact factor: 5.852

4.  A screen for regulators of survival of motor neuron protein levels.

Authors:  Nina R Makhortova; Monica Hayhurst; Antonio Cerqueira; Amy D Sinor-Anderson; Wen-Ning Zhao; Patrick W Heiser; Anthony C Arvanites; Lance S Davidow; Zachary O Waldon; Judith A Steen; Kelvin Lam; Hien D Ngo; Lee L Rubin
Journal:  Nat Chem Biol       Date:  2011-06-19       Impact factor: 15.040

5.  Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases.

Authors:  Stefanie A Krumm; J Maina Ndungu; Jeong-Joong Yoon; Melanie Dochow; Aiming Sun; Michael Natchus; James P Snyder; Richard K Plemper
Journal:  PLoS One       Date:  2011-05-16       Impact factor: 3.240

Review 6.  CDK inhibitors in cancer therapy, an overview of recent development.

Authors:  Mengna Zhang; Lingxian Zhang; Ruoxuan Hei; Xiao Li; Haonan Cai; Xuan Wu; Qiping Zheng; Cheguo Cai
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

7.  CDA: combinatorial drug discovery using transcriptional response modules.

Authors:  Ji-Hyun Lee; Dae Gyu Kim; Tae Jeong Bae; Kyoohyoung Rho; Ji-Tae Kim; Jong-Jun Lee; Yeongjun Jang; Byung Cheol Kim; Kyoung Mii Park; Sunghoon Kim
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

8.  Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation.

Authors:  Lukas K Filak; Simone Göschl; Petra Heffeter; Katia Ghannadzadeh Samper; Alexander E Egger; Michael A Jakupec; Bernhard K Keppler; Walter Berger; Vladimir B Arion
Journal:  Organometallics       Date:  2013-01-17       Impact factor: 3.876

9.  Involvement of cyclin B1 in progesterone-mediated cell growth inhibition, G2/M cell cycle arrest, and apoptosis in human endometrial cell.

Authors:  Li Tang; Yu Zhang; Hong Pan; Qiong Luo; Xiao-Ming Zhu; Min-Yue Dong; Peter Ck Leung; Jian-Zhong Sheng; He-Feng Huang
Journal:  Reprod Biol Endocrinol       Date:  2009-12-07       Impact factor: 5.211

10.  Alsterpaullone, a Cyclin-Dependent Kinase Inhibitor, Mediated Toxicity in HeLa Cells through Apoptosis-Inducing Effect.

Authors:  Chunying Cui; Yuji Wang; Yaonan Wang; Ming Zhao; Shiqi Peng
Journal:  J Anal Methods Chem       Date:  2013-03-12       Impact factor: 2.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.